0001567619-18-001208.txt : 20180815 0001567619-18-001208.hdr.sgml : 20180815 20180815172704 ACCESSION NUMBER: 0001567619-18-001208 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180813 FILED AS OF DATE: 20180815 DATE AS OF CHANGE: 20180815 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Van Naarden Jacob CENTRAL INDEX KEY: 0001661254 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36562 FILM NUMBER: 181021819 MAIL ADDRESS: STREET 1: C/O LOXO ONCOLOGY, INC. STREET 2: ONE LANDMARK SQUARE, SUITE 1122 CITY: STAMFORD STATE: CT ZIP: 06901 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Loxo Oncology, Inc. CENTRAL INDEX KEY: 0001581720 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 462996673 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 281 TRESSER BOULEVARD, 9TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06901 BUSINESS PHONE: 203-653-3880 MAIL ADDRESS: STREET 1: 281 TRESSER BOULEVARD, 9TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06901 4 1 doc1.xml FORM 4 X0306 4 2018-08-13 0 0001581720 Loxo Oncology, Inc. LOXO 0001661254 Van Naarden Jacob C/O LOXO ONCOLOGY, INC. ONE LANDMARK SQUARE, SUITE 1122 STAMFORD CT 06901 0 1 0 0 Chief Business Officer Common Stock 2018-08-13 4 M 0 5500 3.648 A 19200 D Common Stock 2018-08-13 4 S 0 730 157.6155 D 18470 D Common Stock 2018-08-13 4 S 0 3070 158.6619 D 15400 D Common Stock 2018-08-13 4 S 0 1500 159.6893 D 13900 D Common Stock 2018-08-13 4 S 0 200 160.5950 D 13700 D Common Stock 2018-08-14 4 M 0 4500 3.648 A 18200 D Common Stock 2018-08-14 4 S 0 600 159.0820 D 17600 D Common Stock 2018-08-14 4 S 0 3199 159.9070 D 14401 D Common Stock 2018-08-14 4 S 0 701 160.6997 D 13700 D Employee Stock Option (Right to Buy) 3.648 2018-08-13 4 M 0 5500 0 D 2024-06-18 Common Stock 5500 72769 D Employee Stock Option (Right to Buy) 3.648 2018-08-14 4 M 0 4500 0 D 2024-06-18 Common Stock 4500 68269 D The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Represents the aggregate of sales effected on the same day at different prices. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $157.04 to $157.99 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.11 to $159.09 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.26 to $160.23 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.49 to $160.70 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.43 to $159.27 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.46 to $160.35 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.48 to $161.13 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The stock option vested and became exercisable as to 25% of the shares subject to the option on May 12, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. /s/Jennifer Burstein, by power of attorney 2018-08-15